Staedt J, Stoppe G, Kögler A, Riemann H, Hajak G, Rodenbeck A, Mayer G, Steinhoff B J, Munz D L, Emrich D, Rüther E
Department of Psychiatry, Georg August University, Goettingen, Germany.
Biol Psychiatry. 1996 Jan 15;39(2):107-11. doi: 10.1016/0006-3223(95)00087-9.
Elevated levels of central D2 dopamine receptors were found on postmortem examination in cases of human narcolepsy. In vivo investigations using positron emission tomography (PET) and single photon emission tomography (SPET) found no changes of D2 binding in the striatal structures. To investigate whether the elevated D2 receptors in postmortem investigations are due to long-term treatment effects, we applied 123I-labeled (S)-2-hydroxy-3-iodo-6-methoxy-([1-ethyl-2-pyrrolidinyl]methyl) benzamide (IBZM) ([123I]IBZM, a highly selective CNS D2 dopamine receptor ligand) and SPET in narcoleptic patients in the course of treatment with stimulants and/or antidepressants. Before treatment we found no changes in D2 binding in 10 patients (in comparison to 10 normal controls). After treatment (performed in five patients for 3 months) we found changes in D2 binding in four of them, indicating that the results of the postmortem studies could have been influenced by long-term medications. Human narcolepsy seems not to be related to a striatal D2 dopaminergic disturbance.
在发作性睡病患者的尸检中发现中枢多巴胺D2受体水平升高。使用正电子发射断层扫描（PET）和单光子发射断层扫描（SPET）进行的体内研究发现纹状体结构中D2结合无变化。为了研究尸检中D2受体升高是否归因于长期治疗效果，我们在发作性睡病患者使用兴奋剂和/或抗抑郁药治疗过程中应用了123I标记的（S）-2-羟基-3-碘-6-甲氧基-（[1-乙基-2-吡咯烷基]甲基）苯甲酰胺（IBZM）（[123I]IBZM，一种高度选择性的中枢神经系统D2多巴胺受体配体）和SPET。治疗前，我们发现10例患者的D2结合无变化（与10例正常对照相比）。治疗后（5例患者进行了3个月的治疗），我们发现其中4例患者的D2结合有变化，这表明尸检研究结果可能受到长期药物治疗的影响。发作性睡病似乎与纹状体D2多巴胺能紊乱无关。
